Clinic Roundup
FibroGen Inc., of San Francisco, said it expanded an ongoing Phase II study of GF-3019, a human monoclonal antibody against connective tissue growth factor, in patients with idiopathic pulmonary fibrosis.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.